Meet Ed Dybka, General Manager, Ipsen Canada

Ed AstraZeneca01Ed Dybka was appointed to the role of General Manager at Ipsen Biopharmaceuticals Canada Inc. in October 2018.  In this role, he is responsible for overseeing all of Ipsen’s operations across all therapeutic areas in Canada. Ed is a member of the Ipsen North America Leadership Team and the Ipsen Global Leadership Team.

Ed brings to Ipsen a wealth of experience and over 30 years in the pharmaceutical industry within the Canadian market. Prior to joining Ipsen, he led the development of an early stage biotech company as a joint venture between Mars Innovation (Toronto) and The Center for Drug Research and Development (Vancouver).  Ed also spent time as President & CEO of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.

In 2012, Ed led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases. Prior to establishing Almirall in Canada, Ed held a number of executive roles at GlaxoSmithKline Canada including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement.

In addition to his role at Ipsen, Ed is currently Vice-Chair of the board of Life Sciences Ontario and a Director on the board of Clinical Trials Ontario. He is also Vice-Chair of the Health & Biosciences Economic Strategy Table for the Federal Ministry of Health and Ministry of Innovation, Science and Economic Development which recently published a set of foundational recommendations to accelerate the growth of the Health & Biosciences sector in Canada.

Last update 15/10/2018